Old Port Advisors Buys 232 Shares of Sanofi (NASDAQ:SNY)

Old Port Advisors raised its stake in Sanofi (NASDAQ:SNY) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,704 shares of the company’s stock after purchasing an additional 232 shares during the period. Old Port Advisors’ holdings in Sanofi were worth $1,770,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its position in shares of Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the period. DGS Capital Management LLC increased its position in shares of Sanofi by 4.2% during the third quarter. DGS Capital Management LLC now owns 9,623 shares of the company’s stock valued at $555,000 after purchasing an additional 385 shares during the period. Logan Capital Management Inc. raised its stake in shares of Sanofi by 4.6% in the third quarter. Logan Capital Management Inc. now owns 85,189 shares of the company’s stock valued at $4,909,000 after purchasing an additional 3,774 shares in the last quarter. Franklin Resources Inc. lifted its position in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the period. Finally, Tidal Investments LLC boosted its stake in Sanofi by 126.7% during the third quarter. Tidal Investments LLC now owns 13,798 shares of the company’s stock worth $795,000 after buying an additional 7,711 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

NASDAQ:SNY traded up $0.29 during trading hours on Thursday, reaching $48.52. The company had a trading volume of 357,039 shares, compared to its average volume of 2,089,566. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $49.33 and a two-hundred day moving average of $52.03. Sanofi has a one year low of $45.22 and a one year high of $58.97. The firm has a market capitalization of $123.14 billion, a PE ratio of 24.76, a PEG ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. Analysts forecast that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.